All In Biotech

Drug Trial Radar · NCT03748641

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 765 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

765

Actual

Start

Jan 25, 2019

Primary completion

Oct 8, 2021

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.

Conditions

  • Castration-Resistant Prostatic Cancer

Interventions

  • NiraparibDrug

    Participants will receive niraparib 200 mg capsules or tablets once daily.

  • Abiraterone AcetateDrug

    Participants will receive AA 1000 mg tablets once daily.

  • PrednisoneDrug

    Participants will receive prednisone 10 mg tablets daily.

  • PlaceboDrug

    Participants will receive matching placebo once daily.

  • New Formulation of Niraparib and Abiraterone Acetate (AA)Drug

    Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to 32 months
  2. Cohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to 32 months

Locations

318 sites in 29 countries. Site status is shown where the registry gives one.

  • Urology Centers Of Alabama

    Homewood, Alabama

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Urological Associates of Southern Arizona, P.C.

    Tucson, Arizona

  • Arkansas Urology

    Little Rock, Arkansas

  • Kaiser Permanente

    Riverside, California

  • San Bernardino Urological Associates

    San Bernardino, California

  • University of California San Francisco

    San Francisco, California

  • Sansum Clinic Pharm

    Santa Barbara, California

  • The Urology Center of Colorado

    Denver, Colorado

  • Colorado Clinical Research

    Lakewood, Colorado

  • VA Connecticut Healthcare

    West Haven, Connecticut

  • Bay Pines VA Healthcare System

    Bay Pines, Florida

  • Advanced Urology Institute

    Daytona Beach, Florida

  • University of Florida Health Jacksonville

    Jacksonville, Florida

  • Mayo Clinic - Division Of Hematology/oncology

    Jacksonville, Florida

  • Veterans Affairs Medical Ctr

    Hines, Illinois

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana

  • First Urology

    Jeffersonville, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Norton Healthcare

    Louisville, Kentucky

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Rcca Md, Llc

    Bethesda, Maryland

  • Chesapeake Urology Research Associates

    Towson, Maryland

  • Massachusetts General

    Boston, Massachusetts

  • Michigan Institute of Urology

    Troy, Michigan

  • Kansas City Veterans Affairs Medical Center

    Kansas City, Missouri

  • Adult Pediatric Urology & Urogynecology, P.C

    Omaha, Nebraska

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Delaware Valley Urology, LLC

    Mount Laurel, New Jersey

  • New York Oncology Hematology

    Albany, New York

  • Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Upstate Cancer Center

    Syracuse, New York

  • Helios Clinical Research, LLC

    Middleburg Heights, Ohio

  • Oregon Urology Institute

    Springfield, Oregon

  • MidLantic Urology

    Bala-Cynwyd, Pennsylvania

  • Lancaster Urology

    Lancaster, Pennsylvania

  • VA Pittsburgh

    Pittsburgh, Pennsylvania

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

Showing 40 of 318 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.